Lexicon Pharmaceuticals (LXRX) Expected to Announce Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is projected to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.07) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals Stock Up 3.2%

NASDAQ:LXRX opened at $1.61 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64. The company has a market capitalization of $585.19 million, a price-to-earnings ratio of -8.47 and a beta of 0.94. Lexicon Pharmaceuticals has a one year low of $0.30 and a one year high of $1.83. The stock has a 50-day simple moving average of $1.34 and a 200 day simple moving average of $1.32.

Insider Activity at Lexicon Pharmaceuticals

In related news, Director Invus Global Management, Llc bought 1,538,462 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were purchased at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the transaction, the director directly owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Raymond Debbane bought 100,000 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was bought at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the purchase, the director directly owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. The trade was a 5.54% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 1,790,462 shares of company stock worth $2,369,981. Company insiders own 13.90% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

Large investors have recently modified their holdings of the company. Bank of America Corp DE lifted its position in Lexicon Pharmaceuticals by 80.1% in the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 25,707 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $31,000. Hudson Bay Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $26,000. EntryPoint Capital LLC bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $39,000. Finally, Cerity Partners LLC boosted its position in shares of Lexicon Pharmaceuticals by 21.1% during the second quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 35,892 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LXRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $3.97.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.